Thema: Presse: Neue Substanz wird in der Gliomtherapie getestet
Presse: Neue Substanz wird in der Gliomtherapie getestet
Stefan[a]
25.06.2002 08:30:39
Scorpion-Derived Drug to Be Tested Against Glioma
Brain surgeons at the City of Hope in Los Angeles and the University of Alabama at Birmingham plan to test a new drug being developed by TransMolecular, 131I-TM-601, in patients suffering from glioma. 131I-TM-601 is a radiopharmaceutical that contains a synthetic version of a substance derived from scorpions called chlorotoxin.
Researchers involved in the multicenter study will test the safety and tolerability of one 131I-TM-601 dose and overall tumor response rate in the initial study group of 18 patients. Preclinical studies showed that use of 131I-TM-601 could extend survival in a mouse model that mimicked human brain tumors.
The US Food and Drug Administration approved TransMolecular´s investigational new drug application to begin a phase I/II clinical study of the drug in humans in January of this year.
Adult patients with recurrent glioma who have not had prior treatment with gene therapy, brachytherapy, radiosurgery, or implants of polymers containing chemotherapeutic agents are eligible for this study. However, patients must also be eligible for resection of the recurrent tumor. In all, 18 patients will be monitored over 6 months during the study.
Brain surgeons at the City of Hope in Los Angeles and the University of Alabama at Birmingham plan to test a new drug being developed by TransMolecular, 131I-TM-601, in patients suffering from glioma. 131I-TM-601 is a radiopharmaceutical that contains a synthetic version of a substance derived from scorpions called chlorotoxin.
Researchers involved in the multicenter study will test the safety and tolerability of one 131I-TM-601 dose and overall tumor response rate in the initial study group of 18 patients. Preclinical studies showed that use of 131I-TM-601 could extend survival in a mouse model that mimicked human brain tumors.
The US Food and Drug Administration approved TransMolecular´s investigational new drug application to begin a phase I/II clinical study of the drug in humans in January of this year.
Adult patients with recurrent glioma who have not had prior treatment with gene therapy, brachytherapy, radiosurgery, or implants of polymers containing chemotherapeutic agents are eligible for this study. However, patients must also be eligible for resection of the recurrent tumor. In all, 18 patients will be monitored over 6 months during the study.
Stefan[a]
